Tiziana Life Sciences has begun enrollment in a Phase 2 clinical trial for early Alzheimer’s disease, with the first patient expected to be dosed next week. The trial will assess the efficacy of intranasal foralumab as a monotherapy and in combination with the anti-amyloid therapy lecanemab. TSPO-PET imaging has shown persistent neuroinflammation in an Alzheimer’s patient on lecanemab, despite amyloid plaque reduction. Intranasal foralumab is designed to address this residual inflammation by inducing regulatory T cells to calm activated microglia. The trial aims to target neuroinflammation in Alzheimer’s patients, potentially offering a new approach to treatment. Tiziana Life Sciences Ltd issues a caution about relying on forward-looking statements in an announcement. Actual results may differ due to market conditions and other factors. The company will not update these statements unless required by law. For further inquiries, contact Paul Spencer at +44 (0) 207 495 2379 or email [email protected]. Two articles related to Tiziana’s research are available at https://www.pnas.org/doi/10.1073/pnas.2220272120 and https://www.pnas.org/doi/10.1073/pnas.2309221120. Photos can be viewed at the links provided.

Read more at 1. “Tesla announces record-breaking quarterly profits, surpassing expectations” – GlobeNewswire

2. “CDC reports significant drop in COVID-19 cases nationwide” – Reuters

3. “Apple unveils new iPhone with improved camera and longer battery life” – Wall Street Journal

4. “Amazon to hire 75,000 workers across the U.S. and Canada” – CNBC

5. “Facebook faces backlash over handling of misinformation on platform” – CBS MarketWatch: Tiziana Life Sciences to Dose First Patient in Phase 2